PURPOSE: Adrenocortical carcinoma (ACC) is a rare but aggressive endocrine tumor with limited treatment options. Preclinical studies confirmed overexpression of the chemokine receptor 4 (CXCR4) in this cancer type. This study aimed to analyze the role of CXCR4 imaging using Ga-pentixafor for ACC staging and selection of patients for CXCR4-directed endoradiotherapy. METHODS: Thirty patients with histologically proven advanced, metastasized ACC underwent F-FDG PET/CT and Ga-pentixafor PET/CT within a time interval of 3 ± 4 days to evaluate suitability for CXCR4-directed endoradiotherapy. Scans were analyzed retrospectively for visual extent of ACC and SUVmax/mean of the tumor lesions. Ga-pentixafor PET was compared with F-FDG PET, the reference imaging standard. All patients were rated for suitability of CXCR4-directed endoradiotherapy considering patient's history, previous treatment, and CXCR4 expression of FDG-positive lesions compared with background activity within the same organ. RESULTS: All patients had lesions that were positive for both F-FDG and Ga-pentixafor PET and were rated as positive for disease. In 2 patients (7%), Ga-pentixafor PET identified more lesions compared with F-FDG PET. In 5 patients (17%) and 10 patients (33%), complementary and comparable information, respectively, was provided by dual-tracer imaging. In 13 patients (43%), more tumor lesions were identified by F-FDG PET compared with Ga-pentixafor PET. The F-FDG uptake of the malignant lesions was significantly higher (P < 0.01) than the SUVmax/mean for Ga-pentixafor. Overall, 70% of the patients were rated as suitable or potentially suitable for CXCR4-directed treatment. CONCLUSIONS: Ga-pentixafor allows in vivo imaging of CXCR4 expression in patients with advanced ACC and may serve as companion diagnostic tool in selecting patients for potential CXCR4-directed endoradiotherapy. Seventy percent of the patients with advanced, metastasized ACC may be suitable for a CXCR4-directed treatment after failure of standard treatment options.
PURPOSE:Adrenocortical carcinoma (ACC) is a rare but aggressive endocrine tumor with limited treatment options. Preclinical studies confirmed overexpression of the chemokine receptor 4 (CXCR4) in this cancer type. This study aimed to analyze the role of CXCR4 imaging using Ga-pentixafor for ACC staging and selection of patients for CXCR4-directed endoradiotherapy. METHODS: Thirty patients with histologically proven advanced, metastasized ACC underwent F-FDG PET/CT and Ga-pentixafor PET/CT within a time interval of 3 ± 4 days to evaluate suitability for CXCR4-directed endoradiotherapy. Scans were analyzed retrospectively for visual extent of ACC and SUVmax/mean of the tumor lesions. Ga-pentixafor PET was compared with F-FDG PET, the reference imaging standard. All patients were rated for suitability of CXCR4-directed endoradiotherapy considering patient's history, previous treatment, and CXCR4 expression of FDG-positive lesions compared with background activity within the same organ. RESULTS: All patients had lesions that were positive for both F-FDG and Ga-pentixafor PET and were rated as positive for disease. In 2 patients (7%), Ga-pentixafor PET identified more lesions compared with F-FDG PET. In 5 patients (17%) and 10 patients (33%), complementary and comparable information, respectively, was provided by dual-tracer imaging. In 13 patients (43%), more tumor lesions were identified by F-FDG PET compared with Ga-pentixafor PET. The F-FDG uptake of the malignant lesions was significantly higher (P < 0.01) than the SUVmax/mean for Ga-pentixafor. Overall, 70% of the patients were rated as suitable or potentially suitable for CXCR4-directed treatment. CONCLUSIONS:Ga-pentixafor allows in vivo imaging of CXCR4 expression in patients with advanced ACC and may serve as companion diagnostic tool in selecting patients for potential CXCR4-directed endoradiotherapy. Seventy percent of the patients with advanced, metastasized ACC may be suitable for a CXCR4-directed treatment after failure of standard treatment options.
Authors: Finn Holler; Daniel A Heinrich; Christian Adolf; Benjamin Lechner; Martin Bidlingmaier; Graeme Eisenhofer; Tracy Ann Williams; Martin Reincke Journal: Curr Hypertens Rep Date: 2019-09-03 Impact factor: 5.369
Authors: Na Sun; Yin Wu; Kazutaka Nanba; Silviu Sbiera; Stefan Kircher; Thomas Kunzke; Michaela Aichler; Sabina Berezowska; Joachim Reibetanz; William E Rainey; Martin Fassnacht; Axel Walch; Matthias Kroiss Journal: Endocrinology Date: 2018-03-01 Impact factor: 4.736
Authors: Ido D Weiss; Lyn M Huff; Moses O Evbuomwan; Xin Xu; Hong Duc Dang; Daniel S Velez; Satya P Singh; Hongwei H Zhang; Paul J Gardina; Jae-Ho Lee; Liza Lindenberg; Timothy G Myers; Chang H Paik; David S Schrump; Stefania Pittaluga; Peter L Choyke; Tito Fojo; Joshua M Farber Journal: Oncotarget Date: 2017-08-04
Authors: Constantin Lapa; Ken Herrmann; Andreas Schirbel; Heribert Hänscheid; Katharina Lückerath; Margret Schottelius; Malte Kircher; Rudolf A Werner; Martin Schreder; Samuel Samnick; Saskia Kropf; Stefan Knop; Andreas K Buck; Hermann Einsele; Hans-Juergen Wester; K Martin Kortüm Journal: Theranostics Date: 2017-04-08 Impact factor: 11.556
Authors: Irina Chifu; Britta Heinze; Carmina T Fuss; Katharina Lang; Matthias Kroiss; Stefan Kircher; Cristina L Ronchi; Barbara Altieri; Andreas Schirbel; Martin Fassnacht; Stefanie Hahner Journal: Front Endocrinol (Lausanne) Date: 2020-11-13 Impact factor: 5.555
Authors: Malte Kircher; Peter Herhaus; Margret Schottelius; Andreas K Buck; Rudolf A Werner; Hans-Jürgen Wester; Ulrich Keller; Constantin Lapa Journal: Ann Nucl Med Date: 2018-08-13 Impact factor: 2.668